A Randomized Controlled Open-Label Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
